The capital infusion aids the company’s commercialization efforts for its AI-driven surgical navigation platform in the U.S. and overseas.
Seattle-based Proprio designed its Paradigm surgical navigation platform to replace traditional surgical navigation technologies. Using an advanced approach, it avoids the pitfalls that pull attention away from the patient and disrupt workflows. FDA cleared Paradigm in April.
The system uses light field technology and AI to generate a real-time, 3D visualization of surgery. It provides surgeons with the Proprio Volumetric Intelligence, which combines medical images with live data from Paradigm’s sensor suite.
Proprio says its Paradigm system eliminates the need for intraoperative scans, reducing radiation exposur…